Assessment of Executive Functions After Covid-19

Sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04771624
Collaborator
(none)
128
1
12.1
10.6

Study Details

Study Description

Brief Summary

As it is evident that Covid-19 may have some impacts on cognition, the primary aim of this study is to investigate -if any- deficits of attention, working memory and executive functions after Covid-19.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Since Covid-19 (Coronavirus Disease-2019) was declared as a pandemic by the World Health Organization (WHO) on December 31, 2019, it is still widespread and deadly. As an ongoing pandemic, it has led to a panic and then a controlled fear in societies. In many studies, neuropsychological deficits were observed in Covid-19 patients both during the illness and after recovery. A recent study found that impairment in cognitive functions continued after recovery of Covid-19, and it was associated with peripherical inflammatory markers, such as C-Reactive Protein (CRP). CRP, as a peripherical inflammatory marker, has been proven to be inversely related to serum levels of the brain-derived neurotrophic factor (BDNF), an important neurotrophin in the growth and differentiation of neurons. In this study, attention, working memory and executive functions of Covid-19 patients at post-covid period and its relation with the severity of the disease will be investigated.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    128 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    May Covid-19 Impair Executive Functions? A Crossectional Study
    Actual Study Start Date :
    Oct 30, 2020
    Actual Primary Completion Date :
    Apr 30, 2021
    Actual Study Completion Date :
    Nov 1, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Patients

    Subjects who have been Covid positive by RT-PCR at least 60 days ago and not having any symptoms of Covid-19 at the moment

    Healthy

    Subjects who do not have any general medical, neurological or psychiatric disorder

    Outcome Measures

    Primary Outcome Measures

    1. Neuropsychological test scores [Up to 90 days]

      Neuropsychological test scores of Covid-19 patients in comparison with healthy control subjects

    Secondary Outcome Measures

    1. Severity of the disease [Up to 90 days]

      Neuropsychological test score changes according to the disease severity of Covid-19 patients

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    Covid-19 patients:
    • Diagnosed as Covid-19 by RT-PCR at least 60 days but not more than 90 days ago

    • Asymptomatic at the moment

    • Not having any other general medical, neurological or psychiatric conditions except Covid-19 at the time of acute infection

    Healthy subjects:
    • Not having any of Covid-19 symptoms at the testing time point

    • Not having any general medical, neurological or psychiatric condition

    Exclusion Criteria:
    Covid-19 patients:
    • Diagnosed as Covid-19 by RT-PCR less than 60 days or more than 90 days ago

    • Having any symptom of acute phase of Covid-19

    • Having any other general medical, neurlogical or psychiatric contidions

    Healthy subjects:
    • Having any of Covid-19 symptoms at the testing time point

    • Having any general medical, neurological or psychiatric condition

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sağlık Bilimleri Üniversitesi Gazi Yaşargil Training and Research Hospital Diyarbakır Turkey 21070

    Sponsors and Collaborators

    • Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

    Investigators

    • Principal Investigator: Mehmet D Güleken, MD, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Mehmet Diyaddin Güleken, Medical Doctor, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT04771624
    Other Study ID Numbers:
    • 21022021
    First Posted:
    Feb 25, 2021
    Last Update Posted:
    Nov 9, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 9, 2021